Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve financial results for the quarter and half year ended September 30, 2026

October 27, 2026 To, To, Listing/Compliance Department Listing/Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G-Block, Bandra-Kurla Complex, Mumbai – 400001 Bandra (E), Mumbai – 400051 BSE CODE – 543998 NSE Symbol: VALIANTLAB Dear Sir/Madam, Subject: Intimation of Board Meeting Ref: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that a meeting of the Board of Directors of Valiant Laboratories Limited (the ‘Company’) is scheduled to be held on Monday, November 02, 2026, to consider and approve the Standalone and Consolidated Audited Financial Results for the quarter and half year ended September 30, 2026. In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and in terms of the Company’s Code of Conduct for Prevention of Insider Trading in Securities of the Company, we have intimated about the closure of Trading Window vide our letter dated September 29, 2026. The Trading Window shall continue to remain closed till November 04, 2026. This intimation is also being uploaded on the Company’s website at www.valiantlabs.in We request you to take the same on record. Thanking you, Yours faithfully, For Valiant Laboratories Limited Akshay Gangurde Company Secretary & Compliance Officer www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai-400083. T: 022-49717221/49712001/49717220 | E: investor@valiantlabs.in